We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Advice for medical professionals to use when assessing drivers with cardiovascular disorders.
Evidence and guidance to help healthcare professionals to prevent heart attacks, strokes and dementia and to improve cardiovascular health.
A professional resource on improving the detection and treatment of the high-risk conditions atrial fibrillation, high blood pressure and high cholesterol
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in clinical commissioning groups (CCG) areas.
Overview of the UK's cardiovascular disease research infrastructure and advantage of investment in the UK's life science sector to support new treatments.
The outcomes versus expenditure tool shows the relationship between spending on cardiovascular disease (CVD) care and clinical outcomes.
Semaglutide is the first weight loss drug approved in the UK as a preventative treatment for those with established cardiovascular disease
Preventing people in England from developing high blood pressure (hypertension), and detecting and managing it better in those who have it.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).